JP7511551B2 - 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法 - Google Patents

改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法 Download PDF

Info

Publication number
JP7511551B2
JP7511551B2 JP2021518527A JP2021518527A JP7511551B2 JP 7511551 B2 JP7511551 B2 JP 7511551B2 JP 2021518527 A JP2021518527 A JP 2021518527A JP 2021518527 A JP2021518527 A JP 2021518527A JP 7511551 B2 JP7511551 B2 JP 7511551B2
Authority
JP
Japan
Prior art keywords
drα1
domain
seq
binding
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504217A (ja
JP2022504217A5 (https=
Inventor
ロベルト メザ－ロメロ，
アーサー ヴァンデンバーグ，
ハリーナ オフナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of JP2022504217A publication Critical patent/JP2022504217A/ja
Publication of JP2022504217A5 publication Critical patent/JP2022504217A5/ja
Application granted granted Critical
Publication of JP7511551B2 publication Critical patent/JP7511551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021518527A 2018-10-05 2019-10-04 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法 Active JP7511551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741941P 2018-10-05 2018-10-05
US62/741,941 2018-10-05
PCT/US2019/054850 WO2020072992A1 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use

Publications (3)

Publication Number Publication Date
JP2022504217A JP2022504217A (ja) 2022-01-13
JP2022504217A5 JP2022504217A5 (https=) 2022-10-13
JP7511551B2 true JP7511551B2 (ja) 2024-07-05

Family

ID=68296863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518527A Active JP7511551B2 (ja) 2018-10-05 2019-10-04 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法

Country Status (8)

Country Link
US (1) US11945855B2 (https=)
EP (1) EP3860644A1 (https=)
JP (1) JP7511551B2 (https=)
KR (1) KR102925681B1 (https=)
CN (1) CN113164573B (https=)
AU (1) AU2019355062B2 (https=)
CA (1) CA3114446A1 (https=)
WO (1) WO2020072992A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719466A1 (en) * 2023-05-26 2026-04-08 Oregon Health & Science University Treatment of cancer with drq polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142142A1 (en) 2003-09-05 2005-06-30 Burrows Gregory G. Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
JP2015505315A (ja) 2012-01-06 2015-02-19 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
US20150098956A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS
US20180271935A1 (en) 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
WO2015051328A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University TREATMENT OF ISCHEMIC STROKE WITH DRα1-MOG-35-55
WO2017070569A1 (en) 2015-10-23 2017-04-27 Oregon Health & Science University Compounds that bind macrophage migration inhibitory factor
US10689446B2 (en) 2016-06-22 2020-06-23 Oregon Health & Science University Recombinant CD74 polypeptides
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142142A1 (en) 2003-09-05 2005-06-30 Burrows Gregory G. Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
JP2015505315A (ja) 2012-01-06 2015-02-19 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
US20150098956A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS
US20180271935A1 (en) 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Chem. Technol. Biotechnol.，2005年，Vol.80, No.1，pp.2-12

Also Published As

Publication number Publication date
CN113164573A (zh) 2021-07-23
JP2022504217A (ja) 2022-01-13
EP3860644A1 (en) 2021-08-11
WO2020072992A1 (en) 2020-04-09
US20210380660A1 (en) 2021-12-09
AU2019355062B2 (en) 2025-12-18
US11945855B2 (en) 2024-04-02
CN113164573B (zh) 2024-05-31
CA3114446A1 (en) 2020-04-09
KR20210071019A (ko) 2021-06-15
KR102925681B1 (ko) 2026-02-10
AU2019355062A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CA3042582C (en) Antibodies and polypeptides directed against cd127
JP6364352B2 (ja) 部分的ｍｈｃコンストラクト及びその使用方法
US8343500B2 (en) Peptide composition
EP1675607B1 (en) Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
KR102205633B1 (ko) 융합 단백질
JP2008537736A (ja) 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
JP2009029833A (ja) Ｃｄ２８／ｃｔｌａ−４阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
JP7511551B2 (ja) 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法
US8461103B2 (en) Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom
EP2945966B1 (en) Peptide
US10525101B2 (en) Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
JP7685766B2 (ja) 抗ｉｄｅ抗体およびその使用
HK1211596B (en) Peptide
HK1262138A1 (en) Uses of soluble ctla4 mutant molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240625